Webinar | October 20, 2023

Strategies To Accelerate Development And De-Risk Gene Therapy Manufacturing

With its potential to treat a broader set of indications, the number of gene therapies under development is increasing. Concurrently, the need for accelerated and de-risked pathways to manufacturing is vital to delivering these critical therapies to patients. Having a robust process and analytical development (PAD) plan in place from the start is imperative, not only to drive the reduction of timelines, operation risks, and COGs but also to enhance patient safety.

Working with an experienced PAD team, who has the expertise, know-how, and capabilities to guide you in developing robust processes and analytical methods is instrumental to the success of your gene therapy. Join viral vector PAD experts from MilliporeSigma as they showcase strategies for developing robust processes and analytics for efficient and de-risked manufacturing.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma